A | THE PERCEIVED TENSIONS HAVE YET TO IMPACT the biopharmaceutical industry in Mexico in any measurable way. This is not only the overall feeling amongst manufacturing executives in the country, but an assessment also supported by leaders from the National Chamber of the Pharmaceutical Industry (CANIFARMA), the premier organization bringing together national and multinational biopharma manufacturers in Mexico, which has been closely following the developments associated with the most recent Mexico/U.S. North American Free Trade Agreement (NAFTA) negotiations.
RAÚL DIAZ directs MSD Animal Health Large Molecules Biopharm Operations in Montes Claros, Brazil. He has managed Merck manufacturing facilities in Europe, Mexico, and the United States.